Forbes (9/7, Broster) reports that “September marks Gynecological Cancer Awareness Month,” and “according to a new study, 78% of people were unaware of the five different gynecological cancers and 86% didn’t know what symptoms to look out for.” In the study, researchers spoke to 100 women between the ages of 18 and 44, and found “44% […]
Women With Recurrent Ovarian Cancer With Maintenance Use Of Rucaparib May Have Longer Quality-Adjusted PFS And Quality-Adjusted Time Without Symptoms Or Toxicity Compared To Placebo Cancer Therapy Advisor (9/3, Moench) reports researchers conducted an exploratory analysis and found “longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity in women with recurrent ovarian cancer […]
Addition Of Trastuzumab To Carboplatin And Paclitaxel May Increase PFS, OS In Women With Advanced Or Recurrent HER2-Positive Uterine Serous Carcinoma Healio (8/5, DeRosier) reports researchers found in a phase 2 trial that “the addition of trastuzumab to carboplatin and paclitaxel increased PFS and OS for women with advanced or recurrent HER2-positive uterine serous carcinoma.” In […]
Omitting Routine Prophylactic Pegfilgrastim During Paclitaxel Portion Of Treatment Appears Safe And Feasible For Certain Patients With Breast Cancer Healio (7/13, Southall) reports researchers found “omitting routine prophylactic pegfilgrastim during the paclitaxel portion of treatment appeared safe and feasible for certain patients with breast cancer.” The “researchers found no causal relationship between omission of pegfilgrastim and […]
In Women With TPF3-Mutated, Platinum Sensitive Ovarian Cancer, WEE1 Kinase Inhibitor, Plus Carboplatin, Paclitaxel Improved PFS Compared With Chemo Alone Cancer Therapy Advisor (7/8, Lawrence) reports, “Adavosertib, a WEE1 kinase inhibitor, plus carboplatin and paclitaxel improved progression-free survival (PFS) in women with TP53-mutated, platinum-sensitive ovarian cancer compared with chemotherapy alone, according to results from a phase […]
Cancer Therapy Advisor (7/1, Primeau) reports, “Patients with human papillomavirus (HPV)-negative vulvar cancer commonly harbored TP53 mutations, according to results from a whole-exome analysis published in Gynecological Oncology.” Specifically, “sequencing identified integration of viral E7 gene from HPV 16 among 35.3% of samples; the remaining were HPV-negative.” Moreover, “the other most common nonsynonymous mutations occurred in […]
(6/17) reports, “University of British Columbia (UBC) researchers have led an international team in developing a new test to better diagnose different types of ovarian cancer, a tool that could one day guide and improve treatment options for women diagnosed with the most common and deadliest form of the disease.” The test’s development and validation […]
(5/11, Burba) reports researchers found “lymph node status is a predictor of survival in patients with vulvar melanoma [VuM] and vaginal melanoma [VaM].” The study’s authors said, “Lymph node status and mitotic rate are the most important predictors for disease-specific survival. Lymph node status should be assessed in all applicable patients with VuM and VaM. […]
(5/8) the FDA expanded the approval of AstraZeneca and Merck & Co.’s PARP inhibitor Lynparza (olaparib) “to include its use in combination with bevacizumab for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.” The agency’s expanded approval “applies to use of” the combination treatment “by women who […]
According to study results being presented at the virtual session of the Society for Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, the preliminary results gathered from this clinical trial showed strong activity of WEE1-directed therapy in uterine serous carcinoma (USC). The drug targets the WEE1 protein, which regulates the G2/M checkpoint.“Adavosertib demonstrated remarkable activity […]